Targeted protein degradation: mechanistic diversity, therapeutic expansion, and clinical translation.
This review provides a roadmap for translating TPD into transformative therapies and outlines key challenges including novel E3 ligase ligand discovery, tissue selectivity, and acquired resistance, and discusses how covalent fragment screening, artificial intelligence, and expanded E3 ligase repertoires will advance next-generation degraders to fulfill the promise of event-driven pharmacology.